Mineralys Therapeutics is a publicly traded, clinical-stage biotechnology company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Our initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that we are developing for cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease.
Mineralys is a fully remote company.
For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn.
Sí: Mineralys Therapeutics tiene ahora mismo 173 vacantes abiertas en JobsRadar. 2 de ellas se abrieron en los últimos 30 días. 60 de ellas indican el salario, con una mediana de $147,500 al año. Última actualización el 11 de septiembre de 2026 a las 19:27 UTC.